Liver Metastases Studies
TheraSphere for the Treatment of Liver Metastases
Principal Investigator:
Gregory A. Wiseman, M.D.
Email: gwiseman@mayo.edu
Secretary phone: 507-284-4399
Study Coordinator:
Teresa Mettler, RN
Phone: 507-538-0015
An Open Label Trial of TheraSphere in Patients with Liver Metastases from Primary Colorectal Cancer, Neuroendocrine or Non-Colorectal/Non-Neuroendocrine Cancer
Specific Aims:
Primary:
- To evaluate Progression Free Survival (PFS) following TheraSphere treatment, as determined by CT/MRI images according to RECIST criteria.
- To evaluate the safety of TheraSphere treatment at doses of 120 ± 10% Gy in patients with metastatic disease to the liver.